Third-Party Tested ≥98% HPLC Purity — USA Shipped

GH Secretagogues Research Guide

PEG-MGF: Mechanism, Handling & Research Guide

Also known as: MGF, mechano growth factor, PEG-MGF, pegylated MGF, IGF-1Ec, IGF-1 Ec, MGF E-peptide, IGF-1 splice variant

Key Facts

PEG-MGF is a gh secretagogues research peptide. PEG-MGF is a pegylated form of mechano growth factor, an IGF-1 splice variant studied for muscle satellite cell activation and tissue repair. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification IGF-1 splice variant / mechano growth factor (E-domain peptide); pegylated analog
Research Half-Life Native MGF E-peptide is very short-lived (minutes) in solution; PEGylation is intended to extend solution stability. Precise pegylated half-life is not well characterized in peer-reviewed literature.
Form Lyophilized powder
Research Category GH Secretagogues

What is PEG-MGF?

PEG-MGF (pegylated mechano growth factor) is a stabilized analog of the MGF peptide, a splice variant of insulin-like growth factor-1 produced by mechanically stressed muscle tissue. The native MGF E-domain peptide is thought to play a role in activating muscle satellite (stem) cells and initiating repair following exercise-induced damage. PEGylation extends the molecule's half-life in solution, making it a more practical tool for research into muscle regeneration, hypertrophy signaling, and local tissue repair pathways. Supplied as a lyophilized powder for in-vitro and laboratory research use only.

PEG-MGF Research Applications

In published and preclinical research, PEG-MGF has been studied across the following areas:

  • Muscle satellite cell activation research
  • Tissue repair and regeneration studies
  • IGF-1 splice variant signaling
  • Myogenesis and tissue-repair research

PEG-MGF in Research: Study Context

Published preclinical work characterizes MGF (mechano growth factor) as a locally acting splice variant of IGF-1 (human IGF-1Ec) that is upregulated by mechanical loading and tissue injury, with the E-domain peptide examined for a role in activating quiescent muscle satellite cells and myoblast proliferation, and in neurogenesis in aging-brain rodent models; notably, at least one study reported no apparent effect of the MGF peptide on myoblasts or primary muscle stem cells, so the literature is mixed. PEGylation is described as a stabilization strategy and is not a separate validated drug. This material is reconstituted with bacteriostatic water to a defined mg/mL for laboratory research use only; there is no established human concentration because it is not FDA-approved. Researchers should reference the primary literature and document each lot against its Certificate of Analysis (COA).

How PEG-MGF Compares

Researchers frequently evaluate PEG-MGF alongside related compounds:

  • PEG-MGF vs IGF-1 LR3 — LR3 is a systemically acting, IGFBP-resistant full IGF-1 analog; MGF is a local splice-variant E-peptide studied for satellite-cell activation.

PEG-MGF — Frequently Asked Questions

What is the mechanistic relationship between MGF and IGF-1 in the literature?
MGF is a splice variant of the IGF-1 gene (human IGF-1Ec) generated by alternative splicing that introduces an exon-5 insert, yielding a distinct C-terminal E-domain peptide. Preclinical models describe a proposed two-phase scheme in which the MGF E-peptide is associated with activating satellite/progenitor cells while mature IGF-1 is associated with differentiation and fusion. This is a research-stage mechanism, not a clinical finding.
Is the satellite-cell effect of the MGF peptide settled in the literature?
No. Some studies report the E-domain peptide activates quiescent satellite cells and promotes myoblast proliferation, while Fornaro et al. (2014) reported the synthetic MGF peptide had no apparent effect on myoblasts or primary muscle stem cells. The evidence is mixed and remains an open question in preclinical research.
What does PEGylation change for handling and study design?
PEGylation (attaching polyethylene glycol) is used to increase a peptide's hydrodynamic size and reduce clearance/degradation, which is intended to improve stability of the molecule in solution relative to the native E-peptide. Researchers should reconstitute with bacteriostatic water to a defined mg/mL, store reconstituted solution refrigerated, avoid freeze-thaw cycles, and verify identity/purity against the lot COA.
Is PEG-MGF legal to buy for research?
PEG-MGF is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does PEG-MGF come with a Certificate of Analysis?
Yes. Every batch of PEG-MGF from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is PEG-MGF?
PEG-MGF is a pegylated form of mechano growth factor, an IGF-1 splice variant studied for muscle satellite cell activation and tissue repair. It is supplied in 2mg vials and intended strictly for in-vitro and laboratory research use only.
How should PEG-MGF be stored?
PEG-MGF should be stored at -20°C for long-term storage or 2-8°C for short-term use. Keep the vial sealed and protected from light, moisture, and repeated freeze-thaw cycles. Once reconstituted, store at 2-8°C and use within 30 days.
What purity is PEG-MGF?
PEG-MGF is manufactured to a minimum purity of ≥98% as verified by HPLC analysis, with identity confirmed by mass spectrometry. Each batch ships with a Certificate of Analysis (COA).

Research References

  1. Tang JJ et al. Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Molecular Brain 2017.
  2. Fornaro M et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 2014.